Last year, a total of 40 new drugs were licensed in Korea, with five items manufactured by domestic pharmaceutical companies. One item of Yooyoung Pharmaceutical Co., Ltd.'s anti-arthritis treatment and four items of Hwanin Pharmaceutical Co., Ltd. were listed as new drugs. Rare drugs have also been licensed, up sharply from the previous year.
The expedited review of treatments such as Remdesivir was also made due to the epidemic of COVID-19 infectious diseases. Domestic pharmaceutical companies were found to have been active in developing salt modified drugs for compounding drugs and patent avoidance purposes.

The MFDS announced that it published the "Approval report of 2020 drugs" on the 30th of l